Patents by Inventor Yong Liang Zhu

Yong Liang Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted quinoxalines as B-raf kinase inhibitors
    Patent number: 9249110
    Abstract: Described herein are kinase inhibitors represented by Formula I: and pharmaceutical compositions thereof for use in the treatment of cancer.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: February 2, 2016
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Substituted quinoxalines as B-RAF kinase inhibitors
    Patent number: 9249111
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described. Specifically quinoxaline derivatives of Formula I: and their use in modulating the activity of B-raf and/or mutant B-raf kinase to regulate and modulate abnormal or inappropriate cell proliferation, differentiation, or metabolism are disclosed. Also disclosed are methods of treating cancer associated with B-raf and/or mutant B-raf kinase activity in a subject, comprising administering the compounds of Formula I.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: February 2, 2016
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20160009663
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: November 12, 2013
    Publication date: January 14, 2016
    Inventors: Xiangping Qian, Yong-liang Zhu
  • COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    Publication number: 20150290205
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Application
    Filed: January 21, 2015
    Publication date: October 15, 2015
    Inventors: Prabha N. Ibrahim, Dean R. Artis, Ryan Bremer, Gaston Habets, Shumeye Mamo, Marika Nespi, Chao Zhang, Jiazhong Zhang, Yong-Liang Zhu, Rebecca Zuckerman, Brian West, Yoshisa Suzuki, Jianming Tsai, Klaus-Peter Hirth, Gideon Bollag, Wayne Spevak, Hanna Cho, Samuel J. Gillette, Guoxian Wu, Hongyao Zhu, Shenghua Shi
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20150175601
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: August 22, 2014
    Publication date: June 25, 2015
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20150158826
    Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.
    Type: Application
    Filed: September 14, 2012
    Publication date: June 11, 2015
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • INHIBITORS OF POLO-LIKE KINASE
    Publication number: 20150126502
    Abstract: The present invention provides compounds having a structure according to Formula (I): or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventors: Robert A. GALEMMO, Dean R. ARTIS, Xiaocong Michael YE, Danielle Aubele, Anh TRUONG, Simeon BOWERS, Roy K. Hom, Yong-Liang ZHU, R. Jeffrey NEITZ, Jennifer SEALY, Marc ADLER, Paul BEROZA, John P. ANDERSON
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20150057277
    Abstract: Chemical entities that are quinoxaline kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: January 25, 2013
    Publication date: February 26, 2015
    Inventors: Yong-liang Zhu, Xiangping Qian
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20150057276
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: September 20, 2012
    Publication date: February 26, 2015
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Certain chemical entities, compositions, and methods
    Patent number: 8691977
    Abstract: Chemical entities which are triterpenoid derivatives, pharmaceutical compositions and methods of treatment of inflammatory, neurodegenerative, neoplastic and autoimmune diseases are described.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: April 8, 2014
    Assignee: Neupharma, Inc.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    Publication number: 20140038948
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Application
    Filed: June 25, 2013
    Publication date: February 6, 2014
    Applicant: Plexxikon Inc.
    Inventors: Guoxian Wu, Jiazhong Zhang, Yong-Liang Zhu, Chao Zhang, Prabha N. Ibrahim, Songyuan Shi, Wayne Spevak, Dean R. Artis, James Tsai
  • Certain chemical entities, compositions, and methods
    Patent number: 8614211
    Abstract: Chemical entities that are arctigenin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: December 24, 2013
    Assignee: NeuPharma, Inc.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • INHIBITORS OF POLO-LIKE KINASE
    Publication number: 20130331376
    Abstract: The present invention provides compounds having a structure according to Formula (I): or a salt or solvate thereof, wherein ring A, E1, E2, R1, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.
    Type: Application
    Filed: August 14, 2013
    Publication date: December 12, 2013
    Applicant: Elan Corporation, Inc.
    Inventors: Robert A. Galemmo, Dean R. Artis, Michael Ye, Danielle Aubele, Anh Truong, Simeon Bowers, Roy K. Hom, Yong-Liang Zhu, R. Jeffrey Neitz, Jennifer Sealy, Marc Adler, Paul Beroza, John P. Anderson
  • COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    Publication number: 20130303534
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Application
    Filed: March 5, 2013
    Publication date: November 14, 2013
    Inventors: PRABHA N. IBRAHIM, DEAN R. ARTIS, RYAN BREMER, GASTON HABETS, SHUMEYE MAMO, MARIKA NESPI, CHAO ZHANG, JIAZHONG ZHANG, YONG-LIANG ZHU, REBECCA ZUCKERMAN, BRIAN WEST, YOSHISA SUZUKI, JIANMING TSAI, KLAUS-PETER HIRTH, GIDEON BOLLAG, WAYNE SPEVAK, HANNA CHO, SAMUEL J. GILLETTE, GUOXIAN WU, HONGYAO ZHU, SHENGHUA SHI
  • Inhibitors of polo-like kinase
    Patent number: 8541418
    Abstract: The present invention provides compounds having a structure according to Formula (I): or a salt or solvate thereof, wherein ring A, E1, E2, R1, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: September 24, 2013
    Assignee: Elan Pharmaceutical, Inc.
    Inventors: Robert A. Galemmo, Dean R. Artis, Xiaocong Michael Ye, Danielle Aubele, Anh Truong, Simeon Bowers, Roy K. Hom, Yong-Liang Zhu, R. Jeffrey Neitz, Jennifer Sealy, Marc Adler, Paul Beroza, John P. Anderson
  • INHIBITORS OF POLO-LIKE KINASE
    Publication number: 20130231335
    Abstract: The present invention provides compounds having a structure according to Formula (I): or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.
    Type: Application
    Filed: April 17, 2013
    Publication date: September 5, 2013
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: Robert A. Galemmo, Dean R. Artis, Xiaocong Michael Ye, Danielle Aubele, Anh Truong, Simeon Bowers, Roy K. Hom, Yong-Liang Zhu, R. Jeffrey Neitz, Jennifer Sealy, Marc Adler, Paul Beroza, John P. Anderson
  • Inhibitors of polo-like kinase
    Patent number: 8445503
    Abstract: The present invention provides compounds having a structure according to Formula (I): or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: May 21, 2013
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Robert A. Galemmo, Dean R. Artis, Xiaocong Michael Ye, Danielle Aubele, Anh Truong, Simeon Bowers, Roy K. Hom, Yong-Liang Zhu, R. Jeffrey Neitz, Jennifer Sealy, Marc Adler, Paul Beroza, John P. Anderson
  • Compounds and methods for kinase modulation, and indications therefor
    Patent number: 8415469
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: April 9, 2013
    Assignee: Plexxikon Inc.
    Inventors: Prabha N. Ibrahim, Dean R. Artis, Ryan Bremer, Gaston Habets, Shumeye Mamo, Marika Nespi, Chao Zhang, Jiazhong Zhang, Yong-Liang Zhu, Rebecca Zuckerman, Brian West, Yoshisa Suzuki, Jianming Tsai, Klaus-Peter Hirth, Gideon Bollag, Wayne Spevak, Hanna Cho, Samuel J. Gillette, Guoxian Wu, Hongyao Zhu, Shenghua Shi
  • Certain Chemical Entities, Compositions, and Methods
    Publication number: 20130053384
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described.
    Type: Application
    Filed: August 24, 2012
    Publication date: February 28, 2013
    Applicant: NeuPharma, Inc.
    Inventors: Yong-Liang Zhu, Xiangping Qian
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20130040945
    Abstract: Chemical entities that are arctigenin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: August 10, 2012
    Publication date: February 14, 2013
    Inventors: Xiangping Qian, Yong-Liang Zhu